Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

被引:60
作者
Groheux, David [1 ]
Majdoub, Mohamed [2 ]
Tixier, Florent [3 ]
Le Rest, Catherine Cheze [3 ]
Martineau, Antoine [1 ]
Merlet, Pascal [1 ]
Espie, Marc [4 ,5 ]
de Roquancourt, Anne [6 ]
Hindie, Elif [7 ]
Hatt, Mathieu [2 ]
Visvikis, Dimitris [2 ]
机构
[1] Hop St Louis, Dept Nucl Med, Paris, France
[2] CHRU Morvan, INSERM, LaTIM, UMR 1101, F-29609 Brest, France
[3] Miletrie Hosp, Dept Nucl Med, DACTIM, Poitiers, France
[4] Hop St Louis, Breast Dis Unit, Paris, France
[5] Hop St Louis, Dept Med Oncol, Paris, France
[6] Hop St Louis, Dept Pathol, Paris, France
[7] Univ Bordeaux, CHU Bordeaux, Dept Nucl Med, Bordeaux, France
关键词
F-18-FDG PET/CT; Heterogeneity; Textural features; Breast cancer; POSITRON-EMISSION-TOMOGRAPHY; FDG UPTAKE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC IMPACT; TEXTURAL FEATURES; SURVIVAL; IMAGES; ASSOCIATION; PREDICTION; RELEVANCE;
D O I
10.1007/s00259-015-3110-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of this retrospective study was to determine if some features of baseline F-18-FDG PET images, including volume and heterogeneity, reflect clinical, histological or immunohistochemical characteristics in patients with stage II or III breast cancer (BC). Methods Included in the present retrospective analysis were 171 prospectively recruited patients with stage II/III BC treated consecutively at Saint-Louis hospital. Primary tumour volumes were semiautomatically delineated on pretreatment F-18-FDG PET images. The parameters extracted included SUVmax, SUVmean, metabolically active tumour volume (MATV), total lesion glycolysis (TLG) and heterogeneity quantified using the area under the curve of the cumulative histogram and textural features. Associations between clinical/histopathological characteristics and F-18-FDG PET features were assessed using one-way analysis of variance. Areas under the ROC curves (AUC) were used to quantify the discriminative power of the features significantly associated with clinical/histopathological characteristics. Results T3 tumours (>5 cm) exhibited higher textural heterogeneity in F-18-FDG uptake than T2 tumours (AUC <0.75), whereas there were no significant differences in SUVmax and SUVmean. Invasive ductal carcinoma showed higher SUVmax values than invasive lobular carcinoma (p=0.008) but MATV, TLG and textural features were not discriminative. Grade 3 tumours had higher FDG uptake (AUC 0.779 for SUVmax and 0.694 for TLG), and exhibited slightly higher regional heterogeneity (AUC 0.624). Hormone receptor-negative tumours had higher SUV values than oestrogen receptor-positive (ER-positive) and progesterone receptor-positive tumours, while heterogeneity patterns showed only low-level variation according to hormone receptor expression. HER-2 status was not associated with any of the image features. Finally, SUVmax, SUVmean and TLG significantly differed among the three phenotype subgroups (HER2-positive, triple-negative and ER-positive/HER2-negative BCs), but MATV and heterogeneity metrics were not discriminative. Conclusion SUV parameters, MATV and textural features showed limited correlations with clinical and histopathological features. The three main BC subgroups differed in terms of SUVs and TLG but not in terms of MATV and heterogeneity. None of the PET-derived metrics offered high discriminative power.
引用
收藏
页码:1682 / 1691
页数:10
相关论文
共 43 条
[1]   Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach [J].
Aerts, Hugo J. W. L. ;
Velazquez, Emmanuel Rios ;
Leijenaar, Ralph T. H. ;
Parmar, Chintan ;
Grossmann, Patrick ;
Cavalho, Sara ;
Bussink, Johan ;
Monshouwer, Rene ;
Haibe-Kains, Benjamin ;
Rietveld, Derek ;
Hoebers, Frank ;
Rietbergen, Michelle M. ;
Leemans, C. Rene ;
Dekker, Andre ;
Quackenbush, John ;
Gillies, Robert J. ;
Lambin, Philippe .
NATURE COMMUNICATIONS, 2014, 5
[2]   Oncogene Pathway Activation in Mammary Tumors Dictates FDG-PET Uptake [J].
Alvarez, James V. ;
Belka, George K. ;
Pan, Tien-Chi ;
Chen, Chien-Chung ;
Blankemeyer, Eric ;
Alavi, Abass ;
Karp, Joel S. ;
Chodosh, Lewis A. .
CANCER RESEARCH, 2014, 74 (24) :7583-7598
[3]  
[Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers Version 2
[4]   Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer [J].
Apostolova, Ivayla ;
Steffen, Ingo G. ;
Wedel, Florian ;
Lougovski, Alexandr ;
Marnitz, Simone ;
Derlin, Thorsten ;
Amthauer, Holger ;
Buchert, Ralph ;
Hofheinz, Frank ;
Brenner, Winfried .
EUROPEAN RADIOLOGY, 2014, 24 (09) :2077-2087
[5]   Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders [J].
Basu, Sandip ;
Kwee, Thomas C. ;
Gatenby, Robert ;
Saboury, Babak ;
Torigian, Drew A. ;
Alavi, Abass .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (06) :987-991
[6]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[7]   The Effect of Small Tumor Volumes on Studies of Intratumoral Heterogeneity of Tracer Uptake [J].
Brooks, Frank J. ;
Grigsby, Perry W. .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01) :37-42
[8]   18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations [J].
Cochet, Alexandre ;
Dygai-Cochet, Inna ;
Riedinger, Jean-Marc ;
Humbert, Olivier ;
Berriolo-Riedinger, Alina ;
Toubeau, Michel ;
Guiu, Severine ;
Coutant, Charles ;
Coudert, Bruno ;
Fumoleau, Pierre ;
Brunotte, Francois .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (03) :428-437
[9]   Are Pretreatment 18F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? [J].
Cook, Gary J. R. ;
Yip, Connie ;
Siddique, Muhammad ;
Goh, Vicky ;
Chicklore, Sugama ;
Roy, Arunabha ;
Marsden, Paul ;
Ahmad, Shahreen ;
Landau, David .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) :19-26
[10]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].
de Azambuja, Evandro ;
Holmes, Andrew P. ;
Piccart-Gebhart, Martine ;
Holmes, Eileen ;
Di Cosimo, Serena ;
Swaby, Ramona F. ;
Untch, Michael ;
Jackisch, Christian ;
Lang, Istvan ;
Smith, Ian ;
Boyle, Frances ;
Xu, Binghe ;
Barrios, Carlos H. ;
Perez, Edith A. ;
Azim, Hatem A., Jr. ;
Kim, Sung-Bae ;
Kuemmel, Sherko ;
Huang, Chiun-Sheng ;
Vuylsteke, Peter ;
Hsieh, Ruey-Kuen ;
Gorbunova, Vera ;
Eniu, Alexandru ;
Dreosti, Lydia ;
Tavartkiladze, Natalia ;
Gelber, Richard D. ;
Eidtmann, Holger ;
Baselga, Jose .
LANCET ONCOLOGY, 2014, 15 (10) :1137-1146